# Mabwell (Shanghai) Bioscience Co., Ltd. trials: 54 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 54 trials with Mabwell (Shanghai) Bioscience Co., Ltd. as lead sponsor, 20 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Mabwell (Shanghai) Bioscience Co., Ltd.: 54 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/mabwell-shanghai-bioscience-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 54
- Recruiting or not yet: 20
- Read on: November 19, 2026

## Trials

The 25 newest of 54, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 3, 2026 | NCT07914556 | Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 | Recruiting | AML, Multiple Myeloma, CMML | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07914556) |
| September 21, 2026 | NCT07831863 | A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 3 | Not yet recruiting | Lung Squamous Cell Carcinoma | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07831863) |
| August 27, 2026 | NCT07791342 | A Phase I Study of 9MW4113 Injection Versus Dupixent® | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 | Active not recruiting | Healthy Participants | 208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791342) |
| May 8, 2026 | NCT07576608 | A Phase II Study of 9MW3811 in Patients With Pathological Scar | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 2 | Recruiting | Scar | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07576608) |
| April 29, 2026 | NCT07556848 | A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 3 | Not yet recruiting | Locally Advanced or Metastatic Triple-negative Breast Cancer | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07556848) |
| March 12, 2026 | NCT07466160 | A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1/2 | Recruiting | Solid Tumor | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07466160) |
| January 2, 2026 | NCT07314723 | 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 2 | Recruiting | Urothelial Carcinoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07314723) |
| December 18, 2025 | NCT07292714 | A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 2 | Recruiting | Chronic Obstructive Pulmonary Disease COPD | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07292714) |
| December 5, 2025 | NCT07265622 | First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1/2 | Recruiting | Solid Tumors | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07265622) |
| October 14, 2025 | NCT07216560 | First-in-human Study of 7MW4911 in GI Cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1/2 | Recruiting | GI Cancers | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07216560) |
| April 27, 2025 | NCT06947226 | A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1/2 | Not yet recruiting | Solid Tumors | 188 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06947226) |
| April 15, 2025 | NCT06926998 | 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1/2 | Not yet recruiting | Gynecological Malignancies | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06926998) |
| April 3, 2025 | NCT06908928 | A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 | Recruiting | Triple Negative Breast Cancer | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06908928) |
| February 12, 2025 | NCT06823427 | 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 2 | Recruiting | Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Renal... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06823427) |
| February 3, 2025 | NCT06804590 | A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 3 | Completed | Postmenopausal Women Osteoporosis | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06804590) |
| January 14, 2025 | NCT06772766 | A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 | Recruiting | Beta-Thalassemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06772766) |
| December 31, 2024 | NCT06752746 | A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 | Recruiting | Polycythemia Vera | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06752746) |
| November 18, 2024 | NCT06692166 | A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 3 | Recruiting | Cervical Cancer | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06692166) |
| September 19, 2024 | NCT06592326 | 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 3 | Recruiting | Urothelial Carcinoma | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06592326) |
| July 9, 2024 | NCT06492005 | A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 2 | Recruiting | Triple-Negative Breast Cancer | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06492005) |
| April 29, 2024 | NCT06389942 | Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 | Completed | Healthy | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06389942) |
| January 9, 2024 | NCT06196736 | A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 3 | Recruiting | Advanced Urothelial Carcinoma | 432 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06196736) |
| December 18, 2023 | NCT06175351 | Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic... | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1/2 | Active not recruiting | Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06175351) |
| October 12, 2023 | NCT06079112 | 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1/2 | Recruiting | Advanced Urothelial Carcinoma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06079112) |
| August 23, 2023 | NCT06008379 | A Study of 7MW3711 in Subjects With Advanced Solid Tumors | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1/2 | Unknown | Advanced Solid Tumor | 164 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06008379) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 18 |
| Phase 1/2 | 15 |
| Phase 2 | 10 |
| Phase 2/3 | 2 |
| Phase 3 | 9 |

## By status

| Status | Trials |
| --- | --- |
| Unknown | 17 |
| Recruiting | 16 |
| Completed | 13 |
| Not yet recruiting | 4 |
| Active not recruiting | 3 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Pulmonary Disease, Chronic Obstructive | 3 |
| Triple Negative Breast Neoplasms | 3 |
| Carcinoma, Transitional Cell | 3 |
| Asthma | 2 |
| Dermatitis, Atopic | 2 |
| COVID-19 | 2 |
| Neoplasms | 2 |
| Osteoporosis, Postmenopausal | 2 |
| Staphylococcal Infections | 1 |
| Bone Neoplasms | 1 |
| Leukemia, Myeloid, Acute | 1 |
| Myelodysplastic Syndromes | 1 |
| Cicatrix | 1 |
| Polycythemia Vera | 1 |
| Lymphoma | 1 |
| Idiopathic Pulmonary Fibrosis | 1 |
| beta-Thalassemia | 1 |
| Uterine Cervical Neoplasms | 1 |
| Uterine Neoplasms | 1 |
| Genital Neoplasms, Female | 1 |
| Urogenital Neoplasms | 1 |
| Neoplasms by Site | 1 |
| Uterine Cervical Diseases | 1 |
| Uterine Diseases | 1 |
| Pulmonary Fibrosis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Adult education centers in the United States](https://specstream.ai/data/businesses/adult-education-centers/united-states)
- [Endodontics practices in the United States](https://specstream.ai/data/businesses/endodontics-practices/united-states)
- [Orthotics providers in the United States](https://specstream.ai/data/businesses/orthotics-providers/united-states)
- [Wine bars in the United States](https://specstream.ai/data/businesses/wine-bars/united-states)
- [Electronic equipment suppliers in the United States](https://specstream.ai/data/businesses/electronic-equipment-suppliers/united-states)
- [Occupational therapy clinics in the United States](https://specstream.ai/data/businesses/occupational-therapy-clinics/united-states)
